m+Medelevator.RU
← Поиск публикаций
Molecular biology reports · 2025

Exploring protein adenylyltransferase as a therapeutic target for combating ESKAPE pathogens in hospital-acquired infections.

СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Maake Reabetswe, Otun Sarah, Achilonu Ikechukwu

Аннотация

INTRODUCTION: In the face of increasing antimicrobial resistance, ESKAPE pathogens-Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species-pose a significant threat to public health, particularly in nosocomial settings.

AREAS COVERED: This review explores the potential of targeting protein adenylyltransferase (PrAT) as a therapeutic strategy against these multidrug-resistant bacteria. We discuss the mechanisms of PrAT activity, its involvement in reduction-oxidation (redox) homeostasis, and the rationale for its potential as a drug target against ESKAPE pathogens.

EXPERT OPINION: PrAT plays an essential role in sustaining the bacterium's redox homeostasis, a vital aspect of bacterial survival, by interacting with glutaredoxin (Grx). Future research should focus on elucidating the specific role of PrAT in ESKAPE pathogens, with an emphasis on studying the enzyme's function and designing targeted inhibitors. This review underscores the importance of continued investigation into PrAT in ESKAPE pathogens as a critical step in addressing the challenges of antimicrobial resistance in clinical practice.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты